gdc
FDA Approvals, News & UpdatesLeukemiaNewsworthy

Tibsovo First Drug Approved by the FDA for AML with IDH1 Mutation

In July 2018, the FDA approved Tibsovo (ivo-sidenib; from Agios Pharmaceuticals), the first IDH1 inhibitor, for the treatment of adults with relapsed (returning) or refractory (not responding to treatment) acute myeloid leukemia (AML) and a susceptible IDH1 genetic mutation.
October 2018 Vol 4 No 5 – October 17, 2018

In July 2018, the FDA approved Tibsovo (ivo-sidenib; from Agios Pharmaceuticals), the first IDH1 inhibitor, for the treatment of adults with relapsed (returning) or refractory (not responding to treatment) acute myeloid leukemia (AML) and a susceptible IDH1 genetic mutation. On the same day, the FDA approved the RealTime IDH1 test, which is designed to identify the IDH1 mutation. Tibsovo should be used in patients after they had the RealTime IDH1 genetic test to confirm that they have that mutation.

“Tibsovo is a targeted therapy that fills an unmet need for patients with relapsed or refractory AML who have an IDH1 mutation,” said Richard Pazdur, MD, Director of the FDA’s Oncology Center of Excellence. “The use of Tibsovo is associated with a complete remission in some patients and a reduction in the need for both red cell and platelet transfusions.”

This approval was based on a clinical trial of 174 adults with relapsed or refractory AML and a confirmed IDH1 mutation. In about 32% of the patients, the cancer was in complete remission after receiving Tibsovo. It took an average of 2 months to respond to this treatment, and the remission lasted an average of 8.2 months.

Among the most common side effects with Tibsovo were fatigue, increase in white blood cells, joint inflammation/pain, diarrhea, shortness of breath, nausea, mucositis, fever, cough, and constipation.

Recommended For You
FDA Approvals, News & UpdatesLeukemia
Tibsovo Approved for First-Line Treatment of Patients with Acute Myeloid Leukemia and IDH1 Mutation
In May 2019, the FDA approved Tibsovo for the treatment of older patients with newly diagnosed acute myeloid leukemia (AML) and an IDH1 mutation, or for patients with AML who are unable to use intensive chemotherapy.
Breast CancerFDA Approvals, News & Updates
Piqray New Treatment Approved for Metastatic Breast Cancer and PI3KCA Mutation
In May 2019, the FDA approved Piqray (alpelisib), the first PI3K inhibitor for the treatment of metastatic breast cancer with a PI3KCA mutation in postmenopausal women, and in men. An FDA spokesperson said it was the first treatment “to demonstrate a clinically meaningful benefit” for this type of breast cancer.
Bladder CancerFDA Approvals, News & Updates
Balversa First Targeted Drug Approved for Metastatic Bladder Cancer with FGFR Genetic Alterations
In April 2019, the FDA approved Balversa, an FGFR kinase inhibitor, for the treatment of adults with advanced or metastatic bladder cancer and an FGFR genetic alteration, as determined by an FDA-approved diagnostic test. This is the first FDA-approved targeted drug for patients with this specific genetic mutation.
Last modified: October 27, 2018

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.

Country